Christopher Malcuit, Ph.D., is Vice President of Process Sciences at TScan. Chris has nearly two decades of research, development, CMC, and manufacturing experience in the cell therapy industry. Prior to joining TScan, Chris was CMC Lead and Director of Technical Operations at Editas Medicine, where he helped to operationalize the GMP manufacturing of the company’s proprietary Cas12a-based gene editing components for its cell therapy programs to treat hemoglobinopathies. Before joining Editas, Chris held positions of increasing responsibility in Process Development at SQZ Biotechnologies and OvaScience. Chris began his career at Advanced Cell Technology (now Astellas Institute of Regenerative Medicine) working on some of the earliest forms of human therapeutic cloning as well as managing the development and manufacturing of the company’s first embryonic stem cell-derived retinal cell therapy program. Chris holds a Ph.D. in Animal Biotechnology and Biomedical Sciences from the University of Massachusetts, Amherst and has held faculty positions at Worcester Polytechnic Institute and Kent State University.

When not working at TScan, Chris enjoys hiking, fishing, and being an avid supporter of his children’s hockey teams.